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A novel series of phthalimide-dithiocarbamate hybrids was synthesized and evaluated for in vitro inhibitory
potentials against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The anti-cholinesterase results
indicated that among the synthesized compounds, the compounds 7g and 7h showed the most potent anti-
AChE and anti-BuChE activities, respectively. Molecular docking and dynamic studies of the compounds 7g and
7h, respectively, in the active site of AChE and BuChE revealed that these compounds as well interacted with
studied cholinesterases. These compounds also possessed drug-like properties and were able to cross the BBB.
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Introduction
Alzheimer’s disease (AD) is a complex and age-related
neurodegenerative progressive and fatal disorder.[1] It
is estimated that people suffering dementia in 2018
were 50 million worldwide and this statistic is in
progression.[2] Despite many efforts of pharmaceutical
companies and academic institutions, there is no
effective treatment for Alzheimer’s disease. Therefore,
the discovery of new efficient agents for the treatment
of AD is a big challenge for the healthcare community.
Alzheimer’s disease is characterized by shortage of
neurotransmitter acetylcholine (ACh), accumulation of
amyloid plaques, and tau-phosphorylation in the
brain.[3] Therefore, increase of the level of ACh,
decomposition of amyloid plaques, and inhibition of
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tau-phosphorylation and aggregation in the brain are
the most important therapeutic targets for AD.
Furthermore, several studies have suggested that
increase levels brain derived neurotrophic factor
(BDNF) and nerve growth factor (NGF) by experimental
drugs such as J147 can be useful for treatment of
AD.[4] The activity of acetylcholine in the brain is
terminated by acetylcholinesterase (AChE) and there-
fore inhibition of this enzyme led to ameliorate signs
and symptoms of AD.[5] Today, AChE inhibitors such as
donepezil and rivastigmine are the main drugs for the
treatment of AD.[6]
Another one of ACh degrading enzymes is butyr-
ylcholinesterase (BuChE). Recent studies showed that
activity of BuChE in the brain of AD patients with the
progression of the AD increased while AChE activity in
these patients declines. Therefore, inhibition of both
types of ACh degrading enzymes may be beneficial in
AD treatment.[7]
The phthalimide is a bicyclic heterocyclic scaffold
and its derivatives have diverse range of biologically
activities such as anti-inflammatory, anticonvulsant,
hypolipidemic, analgesic, and immunomodulatory
activities.[8–13] Recently, several derivatives of phthal-
imide with high inhibitory activity against AChE have
been reported (Figure 1A and B).[14,15] On the other
hand, two dithiocarbamate derivatives C and D
exhibited good inhibitory activity against cholinester-
ases (Figure 1).[16,17] Keeping in view of the above
mentioned importance of phthalimide and dithiocar-
bamate pharmacophores, herein, we designed, synthe-
sized, and evaluated a novel series of phthalimide-
dithiocarbamate hybrids as new anti-cholinesterase
agents (Figure 1, compounds 7a–7i and 7j–7o).
Figure 1. Design strategy of novel phthalimide-dithiocarbamate hybrids 7 as new anti-Alzheimer agent.
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Results and Discussion
Chemistry
The general procedure for the synthesis of phthalimide
containing dithiocarbamate derivatives 7a–7o is pre-
sented in Scheme 1. It was started from the reaction of
potassium 1,3-dioxoisoindolin-2-ide 1 and appropriate
dibromoalkanes 2a–2c in acetonitrile at 60 °C to give
2-(bromoalkyl)isoindoline-1,3-dione derivatives 3a–3c.
On the other hand, carbon disulfide (4) and primary
amines 5a–5c or secondary amines 5d–5e reacted in
presence of 10% potassium hydroxide in DMF at 50 °C
to produce various sodium dithiocarbamate deriva-
tives 6a–6e. Finally, title compounds 7a–7o were
obtained from the reaction of 2-(bromoalkyl)isoindo-
line-1,3-dione derivatives 3a–3c and sodium dithiocar-
bamate derivatives 6a–6e in DMF at 50 °C.
Pharmacology
ChE Inhibitory Activity. The phthalimide-dithiocarba-
mate hybrids 7a–7o were screened against AChE/
BuChE by the Ellman’s method.[18] Inhibitory activity of
these compounds was compared to standard drugs
rivastigmine and donepezil (Table 1). As can be seen in
Table 1, compounds 7b and 7g–7i were potent
Scheme 1. Synthesis of phthalimide containing dithiocarbamate derivatives 7a–7o. Reagents and conditions: a) Acetonitrile, 60 °C,
6 h; b) Potassium hydroxide 10%, DMF, 50 °C, 3 h; c) DMF, 50 °C, 12 h.
Table 1. Anti-ChE activities of compounds 7a–7o.
Compound IC50 [μM] (AChE)
[a] IC50 [μM] (BuChE)
[a]
7a �100 �100
7b 27.28�0.61 11.7�0.41
7c �100 14.95�0.52
7d �100 �100
7e �100 23.36�0.59
7f �100 �100
7g 4.6�0.18 20.37�0.37
7h 11.72�0.21 8.8�0.24
7i 28.25�0.29 �100
7j �100 20.6�0.33
7k �100 �100
7 l �100 30�0.46
7m �100 �100
7n �100 �100
7o �100 13.6�0.36
Donepezil 0.027�0.003 7.79�0.06
Rivastigmine 11.07�0.01 7.72�0.02
[a] Data are expressed as Mean � SE (three independent
experiments).
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inhibitors against AChE and among them, 7g was the
most potent inhibitor (IC50=4.6�0.18 μM). This com-
pound was 2.5-fold more active than rivastigmine
(IC50=11.07�0.01 μM). Other synthesized compounds
did not show any activity against AChE at 100 μM.
Based on the IC50 values for BuChE, most of the
title compounds exhibited satisfactory inhibitory activ-
ity against BuChE in the range of 8.8�0.24–30�
0.46 μM compared with rivastigmine (IC50=7.72�
0.02 μM) and donepezil (IC50=7.79�0.06). Among
them, compounds 7b, 7c, 7h, and 7o were found to
be more potent inhibitors. Six compounds 7a, 7d, 7f,
7k, 7m, and 7n showed no activity against BuChE at
100 μM.
Structurally, the synthesized compounds are div-
ided into two series: secondary amine derivatives 7a–
7i and tertiary amine derivatives 7j–7o. In each series,
the amine groups and length of the linker between
phthalimide and dithiocarbamate moieties were al-
tered to optimize the anti-ChE inhibitory activity.
The inhibitory activity of secondary amine deriva-
tives 7a–7i against AChE demonstrated that benzylpi-
peridine derivative 7g with methylene linker showed
the most potent activity. Replacement of the meth-
ylene linker to ethylene and propylene led to
decreases of 2.5 and 6 fold inhibitory activity as
observed in the compounds 7h and 7i, respectively. In
this series, cyclohexane derivative 7b with ethylene
linker showed a moderate inhibitory activity against
AChE while it analogs 7a and 7c with methylene and
propylene linkers showed no activity against AChE.
Moreover, phenyl derivatives 7d–7f showed no anti-
AChE activity. Our obtained results were also shown
that tertiary amine derivatives 7j–7o were not active
against AChE.
In the term of BuChE inhibitory activity in secon-
dary amine series 7a–7i, benzylpiperidine derivative
7h with ethylene linker showed most potent activity
while its methylene and propylene analogs 7g and 7i
showed moderate and no activity against BuChE,
respectively. Interestingly, for cyclohexane derivatives
7a–7c and phenyl derivatives 7d–7f, similar to
benzylpiperidine derivatives 7g–7i, the most potent
compounds were compounds containing ethylene
linker (compounds 7b and 7e, respectively). In this
regard, changing ethylene linker to propylene linker in
compound 7b, as in compound 7c, slightly diminished
the activity while replacement of ethylene linker with
methylene linker, as in compound 7a, led to loss of
anti-BuChE activity. Moreover, for phenyl derivatives
7d–7f, replacement of the ethylene linker to meth-
ylene and propylene linkers led to loss of inhibitory
activity against BuChE (compound 7e vs. compounds
7d and 7f).
For the tertiary amine derivatives 7j–7o, phenyl-
piperazine derivative 7o with propylene linker exhib-
ited the highest inhibitory activity against BuChE. The
rest phenylpiperazine derivatives 7j–7k did not show
any activity against BuChE. In this series, two piper-
idine derivatives 7j and 7 l with methylene and
ethylene linkers showed moderate activity while their
propylene analog 7k was inactive against BuChE.
Molecular Docking and Dynamic Studies. Docking
study was performed using by AutoDock 4.2 package
to find the binding modes of the most potent
compounds 7g and 7h in the active site of AChE and
BuChE, respectively. For this purpose, the X-ray crystal
structure of AChE (PDB code: 6O4 W) and BuChE (PDB
code: 4BDS) were retrieved of RCSB protein data bank
(http://www.rcsb.org/pdb/home/home.do).
The applied docking procedure reliability was
validated by re-docking of standard inhibitors donepe-
zil and tacrine over AChE and BuChE, respectively. The
docked conformations corresponding to the lowest
docking score were selected as the most possible
binding modes. The root mean square deviation
(RMSD) was calculated for each ligand to measure the
docking prediction accuracy. The pose was counted
optimal if its RMSD found to be less than 2 Å. The
RMSD of the re-docked conformations of donepezil
and tacrine over 6O4 W and 4BDS was 0.40 Å and
0.29 Å, respectively, which is considered as successfully
docked.[19,20] As a result, the validity of docking
parameters are reasonable in order to predict the
related co-crystalized structures.
Docking of donepezil over AChE active site showed
that the ring center of the benzyl and the indene
moiety interacted with Trp86 and Trp286 via π–π
interactions, respectively. Also, the quaternary amine
of piperidine ring interacts by two π-cation interac-
tions with the ring center of Trp86 and Phe338, as well
the indene carbonyl group forms H-bond interaction
with the backbone N  H of Phe295 (2.3 Å) (Figure 2a)
Furthermore, docking of tacrine over BuChE
showed the prominent role of Trp82 and His438 in
stabilizing the ligand in the binding pocket by
constructing π–π and π-cation interactions with the
aromatic part of acridine moiety and H-bond with the
quaternary amine at the distance of 2.5 Å, respectively
(Figure 2b).
In order to understand the criteria for rational
designing of ChEs inhibitors, it is necessary to uncover
the structural perturbations incurred by the most
potent compounds over ChEs and the effect of these
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compounds on the active site environment. Here, the
stability of protein-ligand complex is defined by RMSD
of the protein’s backbone from its initial to final
conformation over 20 ns MD simulation time. The
RMSD simulation showed that AChE complexed with
7g and donepezil maintained an overall stability
throughout the last 2 and 5 ns of MD time, respec-
tively, with higher fluctuation stabilizing at an average
of 2.2 Å for both systems (Figure 3a and 3b), while the
complex of rivastigmine and 7h complexed with
BuChE displayed longer equilibration time (about the
last 15 ns) with lower fluctuations (Figure 3c and 3d).
The RMSD value of each protein-ligand complex
indicates that the employed simulation time has been
Figure 2. Close-up representation of binding interactions of the superposed docked (green) and co-crystalized donepezil and
tacrine (cyan) over AChE (a) and BuChE (b), respectively, structural waters and their H-bond interaction render in stick.
Figure 3. RMSD of ligand (red) and protein Cα (blue) for 7g-AChE (a), donepezil-AChE (b), 7h-BuChE (c), and 7h-BuChE (d) over
20 ns MD simulation time.
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enough to obtain an equilibrium structure over the
simulation time. Thus, the structures at the MD
equilibrium state used to investigate the structural
specificity of the ligand-protein complexes.
Interaction energies were calculated in order to
reveal ligand-protein stability of AChE/7g, donepezil
or BuChE/7h, rivastigmine (Figure 4). The average total
interaction energy for the compound 7g over AChE
was   10/  20 kcal/mol and for donepezil over AChE
was   20/  30 kcal/mol. Comparing the total interac-
tion energy obtained from MD for the 7g with
donepezil, it was observed that donepezil has more
average total interaction energy (more stable)
throughout 20 ns of simulation time as compared to
that of 7g (Figure 4a and 4b). As the total energy of a
system is the sum of coulomb and Van der Waals (Vw)
energies, this difference originally is due to the more
coulomb energy of donepezil over AChE than com-
pound 7g. According to the experimental assay, high-
er AChE inhibition activity of donepezil rather than 7g
may be related to the more stability and higher
interaction energy of donepezil in comparison with
compound 7g. On the other hand, compound 7h with
higher Vw and total interaction energy than rivastig-
mine (Figure 4c and 4d) show almost the same anti-
BuChE activity which highlight the possibility of
correlation between interaction and inhibitory activity.
Figure 5a and 5c show the detailed ligand atom
interactions that occurred more than 30.0% of the
simulation and Figure 5b and 5d represent
protein  ligand contact bar occupancy during the
20 ns simulations for 7g and donepezil. The interaction
analysis suggests the piperidine NH+ group in 7g
stabilized by π-cation interaction with Trp86 of
catalytic anionic site (CAS) and Tyr341 at the periph-
eral anionic site (PAS), and form H-bond interaction
with Tyr124 of PAS with high occupancy during the
simulation time. In addition, dithiocarbamate moiety
stabilized through water mediated H-bond interac-
tions with Phe295 and Arg296 from the acyl-binding
pocket of CAS. Furthermore, the acyl-binding pocket
of CAS interacts with phthalimide moiety through
Ser293 and Phe338 with H-bond and hydrophobic
interactions (Figure 5a).
Comparison between the binding interactions of
donepezil and 7g with AChE revealed some differ-
ences between the two ligands interactions. The first
Asp74 formed a strong and stable ionic interaction
Figure 4. The variation of interaction energy of the compounds over the AChE and BuChE during 20 ns of MD simulation. Coulomb,
Van der Waals (Vw), and total energy are in red, purple, and green, respectively.
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between piperidine NH+ group in donepezil with 99%
time of simulation (Figure 5c, purple arrow), while the
same NH+ group in 7g stabilized with Trp86, Tyr341,
and Tyr124 as previously mentioned. Although these
interactions have specific role in stabilizing 7g, they
are not as strong as ionic interaction participate in
donepezil by the residue Asp74. Furthermore, by
comparing Figure 5b and 5d the outstanding contribu-
tion of Trp268 related to the PAS residues can be
observed which stabilized the 1-oxoindane group of
donepezil through π–π stacking interactions with
77% time of simulation (Figure 5c, straight green lines).
Consequently, donepezil is regarded as a more stable
ligand in the binding pockets of the AChE, and
subsequently more active compound to inhibit AChE
than compound 7g.
Regards to compound 7h, the benzyl ring and the
dithiocarbamate moiety established π-π and H-bond
interactions with Trp82 and Asn68 at PAS over the
BuChE, respectively. Also, phthalimide moiety dis-
played π-π interaction with Trp231 and Phe329 from
the acyl-binding pocket of CAS. Furthermore, there is a
strong ionic bridge between piperidine NH+ group
and Asp70 (Figure 6a, straight red and blue line) with
77% time of simulation that such strong interaction
has been observed through donepezil and AChE
(Figure 5c). The comparison between the binding
interactions of rivastigmine and 7h over BuChE
represented that although the number of binding
interactions with more that 30% occurrence among
7h and BuChE are remarkably more than existing
binding interactions between rivastigmine and BuChE,
both of them show remarkable ionic interaction with
Asp70 at the PAS (Figure 6c). Therefore, it is expected
that 7h to be as active as rivastigmine against BuChE.
Our molecular dynamics study suggests that the
persistent ionic interaction of ligand with the PAS
residue Asp (Asp74 in AChE and Asp70 in BuChE) has a
significant contribution for ChEs inhibition.
Figure 5. Detailed ligand atom interactions and protein-ligand contact bar analyzed at 20 ns simulations of 7g (a, b) and donepezil
(c, d) over AChE. Interactions that occur more than 30.0% of the simulation time are shown. H-bond, hydrophobic, ionic, and water
bridge are in green, purple, pink, and blue, respectively.
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For analyzing the fluctuation of ChEs residues over
ligand binding interaction, the root mean square
fluctuation (RMSF) was calculated from MD trajecto-
ries. Considering the RMSF plot of 7g and 7h, it was
verified that they are in a good agreement with the
corresponding plots of donepezil and rivastigmine,
respectively (Figure 7). The residues that are bonded to
the ligand were very stable along the simulations (<
2 Å). In the case of BuChE, a larger fluctuation (�2 Å)
was observed for the region relative to residues 281–
283 which are located over the loop at the interface
between the catalytic domain of BuChE and 7h/
rivastigmine binding site. This loop does not interact
with the complexed ligand at the BuChE active site, so
observing higher fluctuation is unavoidable. The
regions showing high fluctuation in AChE-ligand
complex are residues 259 to 264 and residues 493 to
498 that are located to the two side loops far from the
active site and have high solvent exposure. RMSF
results suggested that the complexes of compound 7g
and 7h with the ChE enzyme were able to maintain
their structural and the integrity during the simula-
tions.
Drug Likeliness Parameters. The physicochemical
properties and BBB penetration of the compounds 7g
and 7h as the most potent compounds respectively
against AChE and BuChE were predicted in silico. The
physicochemical properties of these compounds and
standard drugs rivastigmine and donepezil were
obtained using MarvineSketch 5.8.3, ChemDrawUltra
12.0, and Autodock Tools (ver.1.5.4) to assess their
compliance with the Lipinski’s rule of five (a molecular
weight (MW)�500, a number of H-bond acceptors
(HBA)�10, a number of H-bond donors (HBD)�5,
octanol-water partition coefficients (log P)�5, and a
number of rotatable bonds (RBC)�10) and the Veber
rule (polar surface area (tPSA)�140 Å2).[21,22] As can be
seen in Table 2, obtained data revealed that studied
compounds follow the Lipinski’s rule of five and the
Veber rule. The BBB penetration of the compounds 7g,
7h, rivastigmine, and donepezil was predicted by the
admetSAR server.[23] This software predicted that
agents with SVM_MACCSFP BBB score >0.02 were
Figure 6. Detailed ligand atom interactions and protein-ligand contact bar analyzed at 20 ns simulations of 7h (a, b) and
rivastigmine (c, d) over BuChE. Interactions that occur more than 30.0% of the simulation time are shown. H-bond, hydrophobic,
ionic, and water bridge are in green, purple, pink, and blue, respectively.
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able to cross the BBB (Table 2). Obtained results
revealed that studied synthesized compounds similar
to standard drugs were able to cross the BBB.
β-Secretase Inhibitory Activity. One of the most
important approaches for treatment of AD is inhibition
of β-secretase (BACE-1) in order to prevent the
formation of Aβ plaques.[24] Thus, β-secretase inhib-
itory activity of compound 7g as the most active
compound against AChE was obtained via a
fluorescence resonance emission transfer (FRET) meth-
od. For this propose, the kit consisted of β-site amyloid
precursor protein cleaving enzyme 1 (BACE-1) and
Amyloid β-Protein Peptide (APP) based substrate (Rh-
EVNLDAEFK-quencher) was applied and OM99-2
(IC50=0.014 μM) was used as the reference agent.
Obtained results showed that the compound 7g is a
weak inhibitor against β-secretase (Table 3).
Conclusions
In conclusion, we introduced a novel series of
phthalimide-dithiocarbamate hybrids as new cholines-
terase inhibitors. Two series of secondary amine
Figure 7. RMSF values of ChE enzyme from all different systems. 7g-AChE (a), donepezil-AChE (b), 7h-BuChE (c), rivastigmine-BuChE
(d). Peaks indicate areas of the protein that fluctuated the most during the simulation. the background pink, blue and white strips
represented the α-helix and β stands and the loop secondary structures of the enzymes, the ligand binding site represented in
green bar at the bottom of the RMSF plot.
Table 2. Physicochemical properties and BBB penetration of the compounds 7g, 7h, Rivastigmine, and Donepezil.
Entry Rule 7g 7h Rivastigmine Donepezil
MW �500 425 439 250.17 379.21
HBA �10 3 3 2 3
HBD �5 1 1 0 0
LogP �5 3.69 3.69 2.41 4.21
RBC �10 7 7 6 6
Lipinski’s violations – 0 0 0 0
tPSA �140 Å2 52.65 52.65 32.78 38.77
Veber violation – 0 0 0 0
BBB score[a] >0.02 0.056 0.053 0.042 0.103
BBB penetration – + + + +
[a] SVM_MACCSFP BBB Score.
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derivatives 7a–7i and tertiary amine derivatives 7j–7o
were synthesized from appropriate dibromoalkanes,
carbon disulfide, and various amine derivatives. The
results of cholinesterase inhibitory activity revealed
that secondary amine derivatives 7g and 7h were the
most potent compounds against AChE and BuChE,
respectively. Therefore, we made attempt to under-
stand dynamics behavior and the detailed interactions
of the compounds 7g and 7h against AChE and
BuChE, respectively, and compare them with the FDA
approved donepezil and rivastigmine. Our molecular
dynamics study revealed that the complex of these
compounds with the studied ChE was able to maintain
their structural and integrity during the simulations
based on RMSD, RMSF, and energy evaluation study.
Furthermore, docking study revealed the persistent
ionic interaction of the selected ligands with Asp in
the PAS (Asp74 in AChE and Asp70 in BuChE) has a
significant contribution for ChEs inhibition. In silico
pharmacokinetic assay and BBB penetration prediction
demonstrated that compounds 7g and 7h have
satisfactory pharmacokinetics and BBB penetration as
anti-Alzheimer drug candidates.
Experimental Section
Chemistry
Melting points of phthalimide-dithiocarbamate deriva-
tives 7a–7o were measured with a Kofler hot stage
apparatus and are uncorrected. 1H- and 13C-NMR
spectra of the title compounds were recorded with
Bruker FT-400, using TMS as an internal standard. IR
spectra of these compounds were obtained with a
Nicolet Magna FT-IR 550 spectrophotometer (KBr
disks). MS were recorded with an Agilent Technology
(HP) mass spectrometer operating at an ionization
potential of 70 eV. Elemental analysis of the derivatives
7a–7o was performed with an Elementar Analyses
system GmbH VarioEL CHNS mode.
General Procedure for the Preparation of
2-(Bromoalkyl)isoindoline-1,3-dione Derivatives 3
Potassium 1,3-dioxoisoindolin-2-ide (1; 1 mmol) and
acetonitrile was put into a round-bottom flask and
stirred at 60 °C. Then, appropriate dibromoalkanes 2a–
2c (2 mmol) were added dropwise to this mixture for
30 min. After that, the reaction mixture was stirred at
60 °C for 6 h. After completion of the reaction (moni-
tored by TLC), acetonitrile was removed under
vacuum. The obtained precipitate was filtered off and
washed with diethyl ether to give pure compounds 2-
(bromoalkyl)isoindoline-1,3-dione derivatives 3a–3c.
General Procedure for the Preparation of Sodium Dithio-
carbamates 6a–6e
A mixture of different amines 5a–5e (1 mmol) and
10% potassium hydroxide (1 mmol) in DMF (5 ml) was
dissolved and cooled until 0 °C. Then, carbon disulfide
(4; 1.5 mmol) was added dropwise to this mixture for
30 min. The reaction mixture was stirred and heated in
50 °C for 3 h. The reaction progress was monitored by
TLC. After completion of the reaction, the mixture was
cooled to room temperature and a mixture of water/
ice was added and the obtained mixture was filtered
to give sodium dithiocarbamate 6a–6e.
General Procedure for the Preparation of 2-(1,3-Dioxoiso-
indolin-2-yl)alkyl Piperidine-1-carbodithioates 7a–7o
A mixture of 2-(bromoalkyl)isoindoline-1,3-dione deriv-
atives 3a–3c (1 mmol) and sodium dithiocarbamates
6a–6e (1 mmol) in DMF was stirred at 50 °C for 12 h.
Then, the reaction mixture was allowed to cool at
room temperature and poured into crushed ices, and
subsequently, the pure white precipitates were filtered
off. The pure products 7a–7o were obtained by
recrystallization from ethanol.
Biological Evaluation
In Vitro AChE and BChE Inhibition Assay. The inhibitory
potency of the phthalimide-dithiocarbamate hybrids
7a–7o on AChE and BuChE was evaluated using
Ellman’s method.[18] All the synthesized compounds
were dissolved in 1 mL DMSO and 9 mL ethanol and
then four different concentrations (56.3, 11.3, 2.2, and
0.45 μM per well) of each compound were tested to
obtain the range of 20–80% enzyme inhibition for
AChE/BuChE. The reaction mixture included 50 μL
phosphate buffer (0.1 M, pH=8.0), 125 μL of 0.1 M
Table 3. β-Secretase inhibitory activity of compound 7g.
Compound % Inhibition
at 10 μM
% Inhibition
at 50 μM
IC50
[μM][a]
7g 24�12.7 39�14.3 ND
OM99-2 – – 0.014�0.003
[a] Mean�S.E.; values are means of three independent
experiments.
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DTNB, 25 μL of enzyme (2 U/mL of AChE (E.C. 3.1.1.7,
Type V  S, lyophilized powder, from electric eel) or
BuChE (E.C. 3.1.1.8, from equine serum), and 25 mL of
inhibitor solution. The changing of the absorbance
was measured at 412 nm for 2 min (30 s intervals) after
addition of 10 μL substrate (acetylthiocholine iodide or
butyrylthiocholine iodide, 0.15 M) to the reaction
mixture by a multi-well plate reader (Gen5, Power
wave xs2, BioTek, America). The IC50 values were
determined graphically from inhibition curves (log
inhibitor concentration vs. percent of inhibition). All
experiments were performed in 24-well plates on a
Synergy HTX microplate reader in quadruplicates.
Molecular Docking Study
In order to find out the interactions mode of designed
molecules over ChE enzyme, Maestro Molecular Mod-
eling platform (version 11.5) by Schrödinger, LLC was
performed.[25] Initially, the crystal structures of AChE
and BuChE enzymes were retrieved from the Protein
Data Bank (PDB: 6O4 W and 4BDS, respectively) (http://
www.rcsb.org).[26,27] These pdb structures were se-
lected based on criteria like; highest resolution (Å),
being related to Homo sapiens specious, wild type
with no modified residue, and the existence of co-
crystalized ligand. As the prosthetic group and the co-
factors are not directly involved in ChE inhibition, so
they were totally removed before docking investiga-
tion. Except for the four structural waters molecule in
the AChE and BuChE active site, which bridge the
receptor important residues by way of H-bonds and
conserve among other specious, the rest of the water
molecules were removed from the enzymes crystallo-
graphic structures.[28] The 2D structures of the selected
compounds were drawn in Marvin 15.10.12.0 program
(http://www.chemaxon.com) and converted into pdb.
The Protein Preparation Wizard and the LigPrep
module were used to prepare protein and ligand
structure properly.[29–31]
Molecular Dynamic Simulation
Molecular simulations of this study were performed
using the Desmond v5.3 using Maestro interface (from
Schrödinger 2018-4 suite).[32] We evaluated the stabil-
ity of the best drug candidate from the experimental
study; 7g and 7h over AChE and BuChE, respectively,
and compared their perturbation with the standard
inhibitor donepezil and rivastigmine, respectively.
Before the MD simulation, the appropriate pose for
the compounds (7g and 7h) over AChE and BuChE
was determined by Glide docking protocol.[33,34] Glide
application was used for docking investigations using
the standard-precision followed by extra-precision
method with flexible ligand sampling. Post-docking
minimization was performed by applying strain correc-
tion terms. The best docking score poses were used
for conducting MD simulation. In order to build system
for md simulation, the protein-ligand complexes were
solvated with SPC explicit water molecules and placed
in the center of an orthorhombic box of appropriate
size in the Periodic Boundary Condition. Sufficient
counter-ions and a 0.15 M solution of NaCl were also
utilized to neutralize the system and to simulate the
real cellular ionic concentrations, respectively. The MD
protocol involved minimization, pre-production, and
finally production MD simulation steps. In the mini-
mization procedure, the entire system was allowed to
relax for 2500 steps by the steepest descent approach.
Then, the temperature of the system was raised from 0
to 300 K with a small force constant on the enzyme in
order to restrict any drastic changes. MD simulations
were performed via NPT (constant number of atoms,
constant pressure, i. e., 1.01325 bar and constant
temperature, i. e., 300 K) ensemble. The Nose-Hoover
chain method was used as the default thermostat with
1.0 ps interval and Martyna-Tobias-Klein as the default
barostat with 2.0 ps interval by applying isotropic
coupling style. Long-range electrostatic forces were
calculated based on Particle-mesh-based Ewald ap-
proach with the he cut-off radius for coulombic forces
set to 9.0 Å. Finally, this system was subjected to
production MD simulations for 20 ns for each protein-
ligand complex. During the simulation, every 1000 ps
of the actual frame was stored. The dynamic behavior
and structural changes of the systems were analyzed
by the calculation of energy and the root mean square
deviation (RMSD). Subsequently, the energy-minimized
structure calculated from the equilibrated trajectory
system was evaluated for investigation of each ligand-
protein complex.
In Silico Molecular Properties Prediction
The HBA, HBD, and log P values of the compounds 7g,
7h, rivastigmine, and donepezil were calculated using
the MarvineSketch 5.8.3. The tPSA and RBCs of these
compounds were calculated using ChemDrawUltra
12.0 and Autodock Tools (ver.1.5.6), respectively.
Prediction of BBB penetration of the test compounds
Chem. Biodiversity 2019, 16, e1900370
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was performed by online BBB predictor (www.cbli-
gand.org).
BACE1 Enzymatic Assay
β-Secretase inhibitory assay of the compound 7g was
performed exactly according to the manufacturer’s
instruction for BACE1 (β-Secretase) FRET Assay Kit
(Invitrogen. http://tools.invitrogen.com/content/sfs/
manuals/L0724.pdf).
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